Social Media Ideas for Rprx

Latest updates for Rprx

Fresh curated links around RPRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fool.com /4 weeks ago

Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript

Royalty receipts surged 14% as guidance raised for second consecutive quarter.

Read source

seekingalpha.com /2 weeks ago

Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating

Read source

seekingalpha.com /4 weeks ago

Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Read source

seekingalpha.com /2 weeks ago

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

Read source

pharmexec.com /1 month ago

<![CDATA[FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study ]]>

Read source

cafepharma.com /1 month ago

The FDA AdComm Reboot: Part 2; Lessons from the Meeting on Replimune’s RP1

The FDA AdComm Reboot: Part 2; Lessons from the Meeting on Replimune’s RP1 Anonymous (not verified) Fri, 08/07/2026 - 00:29 pharmagather item url The FDA A...

Read source

pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data]]>

Read source

seekingalpha.com /4 weeks ago

RXO, Inc. (RXO) Presents at Deutsche Bank's Chicago Industrials Summit Transcript

Read source

fool.com /4 weeks ago

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Read source

seekingalpha.com /1 week ago

Pfizer-backed Priovant wins FDA approval for lead asset

Read source

pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer]]>

Read source

seekingalpha.com /1 month ago

RXO: Expectations Seem Imaginary As Core Metrics Worsen In Q2

Read source

seekingalpha.com /2 weeks ago

Prelude Therapeutics: A Prognosis After Year-Long Rally

Read source

seekingalpha.com /1 month ago

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

Read source

cafepharma.com /1 day ago

Blenrep

Blenrep Anonymous (not verified) Tue, 09/08/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...

Read source

seekingalpha.com /1 week ago

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Read source

seekingalpha.com /1 month ago

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Read source

cafepharma.com /1 week ago

Praxis

Praxis Anonymous (not verified) Mon, 08/31/2026 - 12:44 field_thread_url https://cafepharma.com/boards/threads/praxis.717326/ board name...

Read source

seekingalpha.com /1 day ago

Rapid7, Inc. (RPD) Presents at Citi's 2026 Global TMT Conference Transcript

Read source

seekingalpha.com /1 month ago

Repligen: Acquisition To Add Cell Therapy Capabilities

Read source

cafepharma.com /1 week ago

Praxis

Praxis Anonymous (not verified) Tue, 09/01/2026 - 12:45 field_thread_url https://cafepharma.com/boards/threads/praxis.717326/ board name...

Read source

seekingalpha.com /1 week ago

Revolution Medicines: Benefit Vs. Reality Compared To Peer Therapeutics

Read source

thefdalawblog.com /1 month ago

The FDA AdComm Reboot: Part 2; Lessons from the Meeting on Replimune’s RP1

By Gayatri R. Rao —

Read source

fool.com /4 weeks ago

Pacira (PCRX) Q2 2026 Earnings Call Transcript

EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.